RNA silencing inhibits mRNA translation. While mRNA translation accounts for the majority of cellular energy expenditure, it is unclear if RNA silencing regulates energy homeostasis. Here, we report that hepatic Argonaute 2 (Ago2)-mediated RNA silencing regulates both intrinsic energy production and consumption and disturbs energy metabolism in the pathogenesis of obesity. Ago2 regulates expression of specific miRNAs including miR-802, miR-103/107, and miR-148a/152, causing metabolic disruption, while simultaneously suppressing the expression of genes regulating glucose and lipid metabolism, including Hnf1β, Cav1, and Ampkα1. Liver-specific Ago2-deletion enhances mitochondrial oxidation and ATP consumption associated with mRNA translation, which results in AMPK activation, and improves obesity-associated pathophysiology. Notably, hepatic Ago2-deficiency improves glucose metabolism in conditions of insulin receptor antagonist treatment, high-fat diet challenge, and hepatic AMPKα1-deletion. The regulation of energy metabolism by Ago2 provides a novel paradigm in which RNA silencing plays an integral role in determining basal metabolic activity in obesity-associated sequelae.
The worldwide prevalence of obesity has reached pandemic proportions, bringing with it a host of associated diseases, such as type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH)\(^1,2\). Obesity develops when energy intake chronically exceeds total energy expenditure. Basal metabolic rate represents the largest component of total energy expenditure, of which the liver is a major organ for energy consumption\(^3\). Protein biosynthesis is one of the most energy-consuming cellular processes in the liver, accounting for \(\sim 20\% - 30\%\) of total energy consumption\(^4,5\). However, despite abundant supply of energy sources and a robust activation of the mammalian target of rapamycin complex (mTORC) pathway, a main driver of protein synthesis\(^6,7,8,9\), the liver-driven energy consumption robustly declined in obesity due to, at least in part, insufficient protein biosynthesis. Suppression of hepatic protein synthesis leads to further accumulation of energy sources associated with obesity-associated pathophysiology, however, the exact mechanism(s) of insufficient protein biosynthesis remains unclear. Hence, defining such molecular mechanism(s) could provide a novel therapeutic approach that alters energy balance in obesity and modulates the pathogenesis of associated sequelae.

Recent studies have revealed significant roles for microRNA (miRNA)-mediated events in the development and progression of obesity and its associated sequela\(^10,11\). Global dysregulation of miRNA expression is triggered in the human and murine obese liver, leading to the induction of the vast majority of miRNAs, including miR-802, miR-103/miR-107, and miR-148a that deteriorate glucose and lipid metabolism in obesity\(^12,13\). As miRNA generally inhibits the translation of target mRNAs through RNA silencing, it is reasonable to hypothesize that these induced miRNAs may contribute to suppression of protein biosynthesis and its associated energy expenditure in obese liver. However, there remain fundamental questions concerning why and how these miRNAs are concurrently induced in the obese condition and whether RNA silencing is integrated into an elaborate adaptive program that cells can elicit to balance anabolic and catabolic processes dependent on energy and metabolic statuses. If RNA silencing plays a role in protein biosynthesis-associated energy metabolism, one would anticipate that individual component(s) of miRNA-regulatory machinery in the liver may impinge on metabolic regulation, and that a nutrient challenge might accentuate the consequences of this regulation.

Argonaute (Ago) family proteins are the main components of the RNA-induced silencing complex (RISC) that carries out RNA silencing. Upon loading of Ago proteins with mature miRNAs produced by the endoribonuclease Dicer\(^17,18\), RISC represses the expression of targeted mRNA through RNA silencing\(^19,20\). Amongst all Ago proteins, Ago2 uniquely possesses an endoribonuclease (“slicer”) activity that generates a specific mature miRNA and cleaves targeted mRNAs in mammals\(^18,21\). To study the role of RNA silencing in hepatic energy homeostasis, we comprehensively evaluated the role of hepatic Ago1 and Ago2, as analyses of these core RISC components might lead to fundamental insights into the link of RNA silencing with energy metabolism. This study demonstrates that hepatic Ago2-mediated RNA silencing regulates energy expenditure during the course of obesity and its inactivation protects from obesity-associated glucose intolerance and hepatic steatosis in mice. Importantly, we discover novel roles of Ago2 in orchestrating the expression of a subset of miRNAs, including miR-802, miR-103/107, and miR-148a, and in the regulation of AMP-activated protein kinase (AMPK) activation linked to protein biosynthesis-mediated energy consumption. This Ago2-mediated RNA silencing is a critical mechanism that connects the dots between protein translation, energy production and consumption, and AMPK activity—disruption of such events is a well-recognized feature in obesity and the pathogenesis of obesity-associated sequelae.

### Results

**Hepatic Ago2 regulates expression of specific miRNAs involved in energy metabolism.** Ago1 and Ago2 are the predominant Ago family members expressed in the liver\(^17,22\). To investigate if RNA silencing is associated with energy and metabolic homeostasis, we generated liver-specific Ago1-deficient (L-Ago1 KO: Ago1\(^{10/12}\) Alb-Cre\(^{10/12}\)) and Ago2-deficient (L-Ago2 KO: Ago2\(^{20/20}\) Alb-Cre\(^{20/20}\)) mice (Supplementary Fig. 1a and b). On control diet (CD), both L-Ago1 KO and L-Ago2 KO mice gained weight similarly to their controls, L-Ago1 WT (Ago1\(^{12/12}\) Alb-Cre\(^{12/12}\)) or L-Ago2 WT (Ago2\(^{20/20}\) Alb-Cre\(^{20/20}\)), and showed no obvious abnormalities during development or in adulthood. In addition, levels of serum alanine aminotransferase (ALT) were comparable between the groups (Supplementary Fig. 1c and d). These results suggest that general functions of the liver are likely unaffected by the absence of Ago1 or Ago2 during development in regular feeding conditions.

Among the Ago proteins, Ago2 uniquely possesses a slicer activity known to contribute to the expression of specific miRNA\(^21-23\) and miRNA cleavage\(^18,26\). In the Ago2-deficient livers, expression levels of Ago1 are increased (Supplementary Fig. 1b), and therefore Ago1 may compensate for Ago2’s nonslicer activity-dependent function. To gain insight into the specific roles of Ago2’s activity in the regulation of liver function, we first assessed the effect of hepatic Ago2-deficiency on miRNA expression profile. Expression profile analyses revealed that the expression levels of 25 miRNAs were significantly reduced in L-Ago2 KO liver, while 8 miRNAs were significantly increased (Fig. 1a, b). Among these significant miRNAs, miR-148a is one of the most abundant miRNAs expressing in the WT liver (Fig. 1b and Supplementary Fig. 2a). In addition, 17 out of 33 total significant miRNAs abundantly expressed were in the top 10 percent of miRNAs expressing in the WT liver (Fig. 1c and Supplementary Table 1). Intriguingly, this group contained miRNAs known to be associated with metabolic diseases (MD-miRNAs) and detrimental to glucose and lipid metabolism, including miR-802, miR-103/107, miR-130a, and miR-148a\(^12,13,27,29\), which were downregulated in the L-Ago2 KO liver (Fig. 1c). We additionally utilized the list of significant miRNAs altered in Ago2 KO liver through the miRNA enrichment pathway analysis by the biological processes and molecular function categories (Fig. 1d). Hepatic Ago2 deficiency affected the functional clusters associated with energy metabolism including fatty acid biosynthesis, AMPK signaling, protein processing, and insulin signaling. Taken together, these results imply the unique role of Ago2 in the expression regulation of a specific repertoire of MD-miRNAs for energy metabolism.

Consistent with these observations, the reduction of MD-miRNAs in L-Ago2 KO liver is accompanied by increased expression of their known target mRNAs, such as hepatocyte nuclear factor 1 homeobox B (Hnf1β), caveolin-1 (Cav1), peroxisome proliferator-activated receptor gamma coactivator 1α (Pgc1α), and low-density lipoprotein receptor (Ldlr), which regulates energy metabolism (Fig. 1e)\(^12,13,29\).

To examine the mechanism by which hepatic Ago2 regulates expression of specific miRNAs, we measured the expression levels of each mature and primary miRNA (pri-miRNA) employing TaqMan probe-based gene expression analysis. Mature miRNA levels of miR-802, miR-107/miR-103, miR-130a, and miR-148a/148b/152, were reduced in L-Ago2 KO liver (Fig. 1f), despite intact expression levels of their pri-miRNAs (Fig. 1g). These results suggest that the miRNA maturation process is impaired in
the Ago2-deficient liver. To further confirm this regulation, we utilized Ago2-deficient mouse embryonic fibroblasts (MEFs) reconstituted with wild type Ago2 (Ago2 WT) or slicer-defective mutant Ago2 (Ago2 Δ669A, or “DA,” containing an aspartate to alanine substitution at residue 669). Expression levels of these MD-miRNAs were increased by reconstitution of Ago2 WT (Supplementary Fig. 2b). Importantly, Ago2 Δ669A mutant only partially induced expression of key MD-miRNAs including miR-107, miR-103, and miR-130a, while expression of miR-148b required Ago2 but not its slicer activity (Supplementary Fig. 2b). While the loss of Dicer also caused a reduction of MD-miRNAs (Supplementary Fig. 2c), these results support a crucial role of Ago2 in the expression of a subset of MD-miRNAs.

While Dicer recognizes the 5’ phosphate end and 2-nucleotide 3’ overhang structure of precursor miRNA for precise and effective biogenesis of miRNAs, recent studies have provided different mechanistic insights into the Ago2-mediated processing of miRNA. One of the proposed characteristics of miRNAs processed by Ago2 is that their precursors have a relatively shorter loop size that likely prevents recognition by Dicer. Moreover, these precursors have no mismatching at position 10 or 11 between guide and passenger strands. The miRNAs with reduced expression in L-Ago2 KO liver tended to have shorter loop sizes than those induced by L-Ago2 KO liver, and had no mismatching at positions 10 or 11 (Supplementary Fig. 2d–f). This information suggests that there may be structural similarities among MD-miRNAs that require Ago2 for maturation.

We next asked if any of the 25 significant miRNAs, Ago1, or Ago2 might have disease associations proximal to their orthologous human miRNAs and genes. To this end, we first identified mouse-human orthologous miRNAs using data from miRBase and miROrtho, identifying a total of 27 human miRNAs (some mouse miRNAs do not have clear orthologs or map to two human miRNAs) (Supplementary Table 2). We then examined a large collection of genetic variants associated with 213 diseases and phenotypes collected from the National Human Genome Research Institute (NHGRI) Catalog of Published Genome-Wide Association Studies (GWAS) that have been expanded to include additional variants in strong linkage disequilibrium (\(r^2 > 0.8\)) with the tagged variants. This analysis revealed that several of the orthologous human miRNAs have proximal GWAS signal, often for relevant phenotypes.
(Supplementary Table 3). For example, a genetic variant (rs6953596) located 245 bases away from the gene encoding miR-148a is strongly associated with body mass index (BMI) in African Americans and thus might act by altering gene regulatory content in these hepatocytes in the absence or presence of pyruvate. Upon the addition of the protonophore carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), Ago2-deficient hepatocytes greatly upregulated catabolic capacities of hepatocytes. To examine the glycolytic rate, the extracellular acidification rate (ECAR) was determined in primary hepatocytes in the absence or presence of pyruvate. The basal ATP/ADP ratio in Ago2-deficient hepatocytes was higher than that in WT controls, and this difference was even greater upon addition of pyruvate (Fig. 2f). Taken together, these data indicate that hepatic Ago2 functions to enhance gluconeogenesis and suppress glucose oxidation while its inactivation results in increased glucose-driven energy production.

**Hepatic Ago2 regulates glucose metabolism in insulin insufficiency.** If hepatic Ago2-deficiency improves systemic glucose metabolism by suppressing gluconeogenesis and accelerating glucose oxidation in the liver, other diabetic conditions may also be improved by hepatic Ago2-deficiency. To examine this possibility, we employed a pharmacological model by administering

---

**Fig. 2 Hepatic Ago2-deficiency improves glucose metabolism.** a Glucose tolerance test performed in L-Ago2 WT (n = 10) and KO (n = 8) mice fed NCD at 20 weeks of age. b Insulin tolerance test performed in L-Ago2 WT (n = 9) and KO (n = 6) mice fed NCD at 21 weeks of age. c Pyruvate tolerance test performed in L-Ago2 WT (n = 9) and KO (n = 10) mice fed NCD at 24 weeks of age. d Glucose production in primary hepatocytes isolated from L-Ago2 WT and L-Ago2 KO incubated in the absence (n = 4 for L-Ago2 WT and L-Ago2 KO, respectively) or presence of 100 or 200 μM Bt-cAMP or pCPT-cAMP (n = 2 for L-Ago2 WT and L-Ago2 KO, respectively). e Extracellular acidification (ECAR) in the absence or presence of 10 mM glucose in primary hepatocytes isolated from L-Ago2 WT (n = 3 for control, n = 6 for glucose) and L-Ago2 KO mice (n = 3 for control, n = 6 for glucose). f Mitochondrial oxygen consumption rate (OCR) in the absence or presence of 2 mM pyruvate in primary hepatocytes isolated from L-Ago2 WT (n = 3 for control and pyruvate, respectively) and L-Ago2 KO mice (n = 3 for control and pyruvate, respectively). g The ATP/ADP ratio in primary hepatocytes isolated from L-Ago2 WT and L-Ago2 KO mice in the absence (n = 6 for L-Ago2 WT and L-Ago2 KO, respectively) or presence of 5 mM pyruvate (n = 6 for L-Ago2 WT and L-Ago2 KO, respectively). Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01
the insulin antagonist peptide, S961 (43 amino acids in length). S961 binds to the insulin receptor and blocks insulin signaling in vivo to acutely induce hyperglycemia. This model allowed us to further assess the role of hepatic Ago2 in glycemic control without the potential confounding effects of body weight and adiposity. After infusing S961 into L-Ago2 WT and L-Ago2 KO mice fed NCD at 12 weeks of age, we examined the effect of hepatic Ago2-deficiency on S961-induced deterioration of glucose metabolism. At this age, while glucose metabolism assessed by GTT was comparable between the genotypes in a PBS-treated control group, S961 treatment caused hyperglycemia in WT mice 1 week after treatment (Fig. 3a), and hyperinsulinemia and glycogenolysis in WT mice after 2 weeks of treatment (Fig. 3b, c). Remarkably, L-Ago2 KO mice are resistant to S961-induced acute glucose intolerance. A heatmap diagram illustrating the differential expression of mature miRNAs in the liver of L-Ago2 WT and KO mice at 2 weeks post PBS or S961 (n = 6, each genotype) treatment. c Hepatic glycogen contents in L-Ago2 WT and KO mice at 2 weeks post PBS or S961 (n = 6, each genotype) or PBS (n = 5, each genotype) treatment. d A heatmap diagram illustrating the differential expression of mature miRNAs in the liver of L-Ago2 WT and KO mice treated with PBS or S961 for 2 weeks. Significant miRNAs differentially expressed between genotypes were identified using DESeq2 (|fold change| > 1.25x and adjusted p < 0.0005). Clusters I and IV are miRNAs differentially expressed between L-Ago2 WT (n = 6) and L-Ago2 KO (n = 6) groups. Clusters II and III are miRNAs differentially expressed by S961 treatment in WT and KO groups, respectively. The log2 expression values were scaled by z-score. e, f Effect of S961-treatment on expression of MD-miRNAs (e) and genes regulating energy metabolism (f) in the liver of L-Ago2 WT and KO mice treated with PBS or S961 (n = 6, each group) for 2 weeks. Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01.
glucose intolerance after 1 week of treatment (Fig. 3a) and S961 treatment of L-Ago2 KO mice resulted in a lower induction of plasma insulin levels and higher hepatic glycogen contents compared with control mice (Fig. 3b, c). These data indicate that inactivation of hepatic Ago2 improves systemic glucose metabolism in the condition of insulin insufficiency.

Expression profiles that assessed the effect of insulin insufficiency on miRNAs in the liver categorized four different classes of miRNAs; (I) dominantly expressed in L-Ago2 WT, (II) induced by S961 in both L-Ago2 WT and KO, (III) suppressed by S961 in both L-Ago2 WT and KO, and (IV) dominantly expressed in L-Ago2 KO (Fig. 3d). Importantly, S961 treatment did not modulate expression levels of miRNAs categorized in class (IV) in both L-Ago2 WT and KO liver. Conversely, several miRNAs in class (I) that contains MD-miRNAs including miR-802, miR-103/107, and miR-130a were strikingly induced by S961 treatment in the WT liver in an Ago2-dependent manner (Fig. 3d, e). These analyses implicate hepatic Ago2-dependent miRNAs play a role in the disruption of glucose metabolism under the condition of insulin insufficiency. Despite the decrease of miR-802 and miR-103/107 expression in the Ago2-deficient condition, expression levels of their known targets, Hnf1β and Cav1, were comparable between the genotypes even in PBS-treated groups at this age (Fig. 3f). While expression of glucose-6-phosphatase (G6Pase), a gluconeogenic gene, was similarly induced between the genotypes (Fig. 3f), expressions of genes critical for mitochondrial function, such as Pgc1α, peroxisome proliferator-activated receptor alpha (Ppara), mitochondrial transcription factor (Tfam), and citrate synthase (Cs) were higher in the liver of L-Ago2 KO mice. These results, along with the Ago2-deficient hepatocyte analyses, suggest that Ago2 regulates the program of a subset of miRNAs involved in energy metabolism, which may be associated with enhancement of gluconeogenesis and suppression of glycolysis and hepatic mitochondrial oxidation induced by insulin insufficiency.

Critical roles of hepatic Ago2 in energy metabolism on high-fat-diet challenge. We next asked if nutrient challenge might accentuate Ago2’s role in metabolic regulation. We thus employed a high-fat diet (HFD)-induced obesity model that induces insulin resistance, glucose intolerance, and hepatic steatosis. We placed L-Ago2 KO, and L-Ago1 KO, and control WT mice on HFD or a control diet (CD), commencing at 4 weeks of age (Fig. 4a and Supplementary Fig. 3a). Of note, the body weights of the HFD-fed L-Ago2 KO mice became lower than that of controls and the difference reached statistical significance at 22 weeks of age (Fig. 4a). Conversely, the body weight of L-Ago1 KO mice was comparable to controls in the HFD condition (Supplementary Fig. 3a). The improvements in glucose metabolism observed in the HFD-fed L-Ago2 KO were even more pronounced when compared to the CD-feeding condition, as assessed by GTT, ITT, and PTT (Fig. 4b, c and d). The improvements were not observed in L-Ago1 KO fed HFD (Supplementary Fig. 3b–d). Consistent with improved systemic glucose tolerance and insulin sensitivity in L-Ago2 KO mice, HFD-induced pancreatic β-cell proliferation and islet hypertrophy were attenuated compared to L-Ago2 WT mice (Supplementary Fig. 4c–g), supporting that hepatic Ago2-deficiency improves insulin sensitivity in the pathogenesis of obesity.

To further demonstrate the role of hepatic Ago2, we performed the hyperinsulinemic-euglycemic clamp study to examine the whole-body glucose metabolism and insulin sensitivity. Glucose infusion rates (GIR) during the clamp studies indicated that L-Ago2 KO mice required significantly higher levels of glucose infusion to maintain blood glucose consistent with increased insulin sensitivity (Fig. 4e and Supplementary Fig. 4h). Insulin clearance and glucose uptakes in gastrocnemius muscle, visceral fat, and subcutaneous fat tissues. 

h Suppression of hepatic glucose production (shGP) during the clamp. Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01
hepatic glucose production was significantly suppressed in L-Ago2 KO mice (Fig. 4h and Supplementary Fig. 4k). These studies indicate that the liver is the main locus responsible for improving systemic insulin sensitivity and glucose metabolism in L-Ago2 KO mice.

Importantly, the liver of L-Ago2 KO mice was characterized by lowered liver weights and triglyceride content, accompanied by lower serum ALT levels on HFD (Fig. 5a–c). In addition, plasma triglyceride levels were lower in L-Ago2 KO mice fed HFD, while those of cholesterol, phospholipids, and free fatty acids were comparable between the genotypes (Supplementary Fig. 5a–d). There was also a reduction in hepatic fatty infiltration as visualized by haematoxylin and eosin (H&E) staining (Fig. 5d). While levels of genes involved in lipid biosynthesis such as stearoyl-CoA desaturase-1 (Scd1) and fatty acid synthase (Fasn) were comparable between the genotypes, those of carnitine palmityltransferase 1A (Cpt1a) and acetyl-coenzyme A synthetase 2-like (Acsl1) that mediate catabolic processes of fatty acids were increased in the livers of L-Ago2 KO mice (Fig. 5e). Consistently, mitochondrial OCR in response to palmitate and acetate, whose circulating levels are positively correlated with obesity and its related sequelae39, was significantly higher in Ago2-deficient hepatocytes compared to controls (Fig. 5f). These cellular phenotypes could promote reduction of hepatic triglyceride accumulation and lowered hepatic steatosis levels we have observed in the liver of L-Ago2 KO mice fed HFD. Quantitative Magnetic Resonance technology (EchoMRI) analyses revealed that total body fat mass in L-Ago2 KO mice is lower than in WT controls (44.3% fat reduction in L-Ago2 KO: p < 0.05, t-test) (Supplementary Fig. 5e), while lean mass composition of L-Ago2 KO mice was slightly higher than that of control mice on HFD at 20 weeks of age (Supplementary Fig. 5f). In addition, the ability to utilize fat mass, which was calculated by measurements of fat and lean compositions before and after an overnight fast, was higher in L-Ago2 KO mice on HFD compared to WT controls (1.675-fold higher in L-Ago2 KO: p < 0.01, t-test) (Fig. 5g). In support of these observations, there was an increased copy number of mitochondrial-DNA (mtDNA) in the Ago2-deficient liver in obesity (Fig. 5h). Consistently, rates of energy expenditure of L-Ago2 KO mice fed HFD for 12 weeks were significantly higher than those of controls (Fig. 5i and Supplementary Fig. 5g and h), despite no significant changes in body weight, total physical activity, food intake, or amounts of fecal lipids between genotypes (Supplementary Fig. 5i–l). We performed similar experiments with L-Ago1 WT and L-Ago1 KO mice fed HFD and found that there were no differences in the regulation of energy homeostasis between the genotypes (Supplementary Fig. 3g–m). Taken together, these data indicate that inactivation of Ago2, but not Ago1, in the liver increases mitochondrial capacity and energy expenditure, which appears to link to improvement of obesity-associated pathophysiology.

Ago2-mediated RNA silencing regulates expression of genes involved in energy metabolism. To investigate molecular mechanisms by which Ago2 orchestrates hepatic energy metabolism, we additionally profiled hepatic miRNA expression under the condition of HFD (Fig. 6a). Utilizing the list of significant miRNAs on HFD, the miRNA target pathway enrichment...
WT and L-Ago2 KO groups were identified. The regulation of glucose and lipid metabolism in the liver. Data are shown as the mean ± SEM. * indicates significance (p < 0.05) and MicroT threshold < 0.8. Pathways unrelated to liver functions were excluded in this pyramid plot. ** Expression levels of specific MD-miRNAs in the liver of L-Ago2 WT mice (n = 8) fed NCD at 25 weeks of age, and L-Ago2 WT (n = 7) and L-Ago2 KO (n = 5) mice fed HFD at 23 weeks of age. ** Expression levels of MD-miRNAs' target mRNAs and pri-miRNAs in the liver of L-Ago2 WT (n = 7) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. ** Compared expression levels of Ampka1, miR-148/152, and their pri-miRNAs in primary hepatocytes isolated from L-Ago2 WT and L-Ago2 KO mice. ** Relative luciferase activity by which Ampka1 3'UTR with or without harboring a mutation at miR148/152 putative target site was assessed in primary hepatocytes isolated from L-Ago2 WT (n = 4 for control, n = 6 for Ampka1 3'UTR and Ampka1 3'UTR-M, respectively) and L-Ago2 KO mice (n = 4 for control, n = 6 for Ampka1 3'UTR and Ampka1 3'UTR-M, respectively). ** Quantification of Ampka1, Cs, and β-actin mRNA levels in fractions collected from polysome profiles of primary hepatocytes isolated from L-Ago2 WT and L-Ago2 KO mice. The graphs show the quantification of the results. A proposed role of hepatic Ago2 in the regulation of glucose and lipid metabolism in the liver. Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01.

**Fig. 6** Hepatic Ago2 regulates expression of MD-miRNAs and Ampka1 in obesity. A, A heatmap diagram illustrating the differential expression of mature miRNAs in the liver of L-Ago2 WT (n = 3) and L-Ago2 KO (n = 3) mice fed HFD for 16 weeks. Significant miRNAs differentially expressed between L-Ago2 WT and L-Ago2 KO groups were identified using DESeq2 (fold change > 2x and adjusted p < 0.05) and plotted as a heatmap using z-score. B, Metabolic pathway enrichment analysis of miRNAs significantly up-regulated (blue) and down-regulated (red) miRNAs in the liver of L-Ago2 KO mice fed HFD for 16 weeks. These miRNAs were queried to calculate the most enriched KEGG pathways using DIANA-mirPath web-server (p < 0.05 and MicroT threshold < 0.8). Pathways unrelated to liver functions were excluded in this pyramid plot. C, Expression levels of specific MD-miRNAs in the liver of L-Ago2 WT mice (n = 8) fed NCD at 25 weeks of age, and L-Ago2 WT (n = 7) and L-Ago2 KO (n = 5) mice fed HFD at 23 weeks of age.
analysis revealed that hepatic Ago2 deficiency affected several functional clades such as glucose and lipid metabolism and protein translation regulation (Fig. 6b). While Ago2 protein levels were slightly decreased in the liver of mice fed HFD (Supplemental Fig. 6a), several MD-miRNAs were highly induced in the liver of L-Ago2 WT mice fed HFD and a leptin-deficient (ob/ob) obese mice (Fig. 6c and Supplemental Fig. 6b). Importantly, expression levels of these genes were comparable between L-Ago1 WT and L-Ago2 KO liver (Supplementary Fig. 3n).

To explore targets of Ago2-dependent MD-miRNAs for metabolic regulation, we then took a bioinformatics approach with miRNA sequencing data obtained under lean, HFD, and S961-treated conditions (Supplementary Fig. 6c and d). With the Ago2-dependent miRNAs, we extracted lists of predicted conserved target genes involved in energy metabolism from the widely used TargetScan 7.1 website. This analysis identified a subset of genes, including Ampkal1 (also known as Prkaal1, a catalytic subunit of AMPK that plays a critical role in AMPK activation) and Cs, that have 3' untranslated region (UTR) containing multiple target sites for Ago2-dependent miRNAs including Mir-148a/152 known to evoke hyperlipidemia, hypercholesterolemia, and atherosclerosis14,15 (Supplementary Fig. 6e and f). As AMPK is known as a critical regulator of energy metabolism, we further assessed the role of Ago2 in Ampkal1 expression. Analyzing a public database of photoactivatable ribonucleoside-enhanced crosslinking and

**Fig. 7** Hepatic Ago2-deficiency enhances energy expenditure associated with protein synthesis and AMPK activation. a, b Western blot analyses of AMPK expression and activation (a) and mRNA expression of the Tfam-mitochondrial genes (b) in the liver of L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) fed HFD at 25 weeks of age. c, d ATP, ADP, and ATP/ADP ratio levels in L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. ATP/ADP ratio levels were independently measured with a distinct procedure from the ATP and ADP assays. d, e Western blot analysis of total and specific protein levels normalized by 12S-genomic DNA in the liver of L-Ago2 WT (n = 5) and KO (n = 5) mice fed HFD at 30 weeks of age. e Serum albumin levels in L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. f Energy consumption rate measured in primary hepatocytes isolated from L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. g Energy consumption rate measured in primary hepatocytes isolated from L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. h Energy consumption rate measured in primary hepatocytes isolated from L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age. i Energy consumption rate measured in primary hepatocytes isolated from L-Ago2 WT (n = 5) and L-Ago2 KO (n = 5) mice fed HFD at 25 weeks of age.
immunoprecipitation (PAR-CLIP) with Ago2\textsuperscript{40} revealed that Ago2 binds to the region of the \textit{Ampkα1} 3′ UTR that contains binding sites of Ago2-dependent miRNAs including miR-148/152 and miR-130a (Supplementary Fig. 6g). Consistent with these findings, we confirmed the induction of \textit{Ampkα1} expression, accompanied by the reduction of miR-148a, miR-148b, and miR-152, in the liver of L-Ago2 KO mice fed HFD and in Ago2-deficient primary hepatocytes (Fig. 6d, i). We next conducted luciferase assays in which \textit{Ampkα1}′s 3′ UTR, with or without harboring a mutation at the miR-148/152 target site, was subcloned into luciferase expression vector. The luciferase activity of each was measured in primary hepatocytes isolated from L-Ago2 WT and KO mice. Luciferase activity was higher in Ago2 KO hepatocyte transfected with \textit{Ampkα1} 3′ UTR without a mutation compared with Ago2 WT hepatocyte, but the induction in Ago2 KO hepatocyte disappeared in the setting with mutated \textit{Ampkα1} 3′ UTR (Fig. 6f). These analyses demonstrated that miR-148/152 are involved in suppression of \textit{Ampkα1} expression in a manner dependent on Ago2 and a miR-148/152 target site (Fig. 6f). As miRNA inhibits the translation of target mRNAs through RNA silencing, we additionally asked if Ago2-deficiency affects translation of genes having target sites of MD-miRNAs by investigating polyosome-bound mRNA expression patterns. Expression levels of polysome-bound \textit{Ampkα1} and \textit{C3} were enriched in Ago2-deficient primary hepatocytes, while those of \textit{β-Actin} were comparable (Fig. 6g). Taken together, these findings further confirm that hepatic Ago2-mediated MD-miRNA expression and RNA silencing are linked to expression regulation of genes involved in energy metabolism (Fig. 6h).

**Hepatic Ago2 regulates energy consumption associated with AMPK activation.** We next examined \textit{Ampkα1} protein levels and noticed that Ago2 deficiency increased not only the protein levels but also activity of AMPK, assessed by phosphorylation levels of AMPKα, AMPKβ, and an AMPK substrate, Acetyl-CoA carboxylase (ACC), in the liver of L-Ago2 KO mice fed HFD and treated with S961 (Fig. 7a and Supplementary Fig. 7a and b). In agreement with the activation of AMPK, other AMPK substrates, UNC-51-like kinase 1 (ULK1), and Mitochondrial fission factor (MFF) are increased in the liver of L-Ago2 KO mice (Supplementary Fig. 7a), suggesting enhanced autophagy/mitophagy and improved mitochondrial quality in the Ago2-deficient liver in obesity. Consistently, expression levels of the Tfam mitochondrial gene pathway are increased in the liver of L-Ago2 KO mice fed HFD (Fig. 7b).

AMPK is activated when cellular energy level becomes low. Indeed, we found a profound induction of ADP levels in the Ago2-deficient liver, while ATP levels are comparable between the genotypes, leading to a reduction of ATP/ADP ratio in the liver of L-Ago2 KO mice fed HFD (Fig. 7c). While Ago2-deficiency enhances capacity for mitochondrial oxidation and ATP production in hepatocytes (Figs. 2g, 5f), systemic energy expenditure is also increased (Fig. 5i). Therefore, we hypothesized that both energy production and consumption are enhanced in the liver of L-Ago2 KO mice compared to their controls. Since a main function of Ago2 is to suppress protein translation, which is one of the most energy consuming cellular processes, through RNA silencing, we investigated the effect of Ago2-deficiency on protein synthesis in the liver. Levels of total and specific proteins normalized by DNA contents were higher in the liver of L-Ago2 KO mice (Fig. 7d and Supplementary Fig. 7c). Similarly, examination of the levels of hepatic and serum albumin, one of the most abundant circulating proteins produced by the liver, revealed that the albumin levels were increased in L-Ago2 KO mice compared to their controls (Fig. 7d, e). These observations suggest that enhanced protein synthesis in the liver may result in a lowered ATP/ADP ratio and AMPK activation in L-Ago2 KO mice.

To further examine if Ago2 deficiency accelerates cellular energy consumption associated with protein synthesis, we treated primary hepatocytes with metformin, which is an anti-diabetic drug and inhibits mitochondrial respiratory-chain complex I activity restricting ATP generation\textsuperscript{41}, and measured ATP/ADP levels. Consistent with enhanced capacity for energy production in Ago2-deficiency (Fig. 2g), relative ATP/ADP levels were higher in Ago2-deficient hepatocytes compared to controls, however, the levels were rapidly decreased post-metformin treatment, suggesting a higher energy consumption rate in Ago2-deficiency (Fig. 7i). Consistently, levels of metformin-induced AMPK activation in Ago2-deficient hepatocytes were significantly higher than that in controls (Fig. 7g). To directly investigate the effect of Ago2-deficiency on protein synthesis in hepatocytes, we measured the levels of nascent protein synthesis. Compared to WT controls, the levels were significantly increased in Ago2-deficient hepatocytes (Fig. 7h). By restricting energy supply using phenformin and rotenone, both of which inhibit mitochondrial respiratory-chain complex I activity, the levels of nascent protein synthesis in Ago2-deficient hepatocytes were equivalent or still higher compared to those in controls (Fig. 7g).

Since Ago2′s slicer activity uniquely regulates RNA silencing, we then asked if the slicer activity is involved in the regulation of energy consumption and AMPK activation. Ago2-deficient MEFs were characterized by enhanced expression of \textit{Ampkα1}, and reconstitution of the MEFs with WT Ago2 suppressed expression of both \textit{Ampkα1} mRNA and AMPKα protein, whereas the Ago2 D669A mutant did not (Supplementary Fig. 8a). We also observed that AMPK activity, assessed by phosphorylation levels of AMPKα and ACC, was higher in Ago2-deficient MEFs under serum starvation condition (Supplementary Fig. 8a). While activated AMPKα is known to suppress mRNA translation\textsuperscript{42}, levels of nascent protein synthesis in Ago2-deficient MEFs are increased compared to the cells reconstituted with WT Ago2 (Supplementary Fig. 8b). To investigate if enhanced protein synthesis reasons AMPK activation in Ago2 deficiency, we treated MEFs with cycloheximide (CHX), a protein synthesis inhibitor, and monitored AMPK activation. Inhibition of protein synthesis resulted in reduction of AMPK activation in WT MEFs, and the effect became more robust in Ago2-deficient MEFs, indicating that Ago2 suppresses protein synthesis-mediated energy consumption (Supplementary Fig. 8c). Taken together, these results indicate that, in addition to an increase of \textit{Ampkα1} expression, there is enhanced energy consumption associated with protein synthesis, leading to the lowered ATP/ADP ratio, which appears to enhance AMPK activation in Ago2-deficient conditions (Fig. 7i).

**Hepatic Ago2 deficiency improves glucose metabolism in a hepatic \textit{Ampkα1}-deficient condition.** While hepatic Ago2-deficiency reduces expression of a specific repertoire of MD-miRNAs of which some of them target \textit{Ampkα1}, it is obvious that changes in expression of these miRNAs also affects translation of other target mRNAs. Similarly, enhanced protein synthesis in the liver of L-Ago2 KO mice must influence not only AMPK activation but also other cellular events linked metabolic regulation. To clarify the role of \textit{Ampkα1} in the metabolic alterations in L-Ago2 KO mice, we generated liver-specific \textit{Ampkα1}- and Ago2-deficient mice (L-DKO mice) and placed them and their control groups, L-Ampkα1 WT and L-Ampkα1 KO mice, on HFD for analyses of glucose metabolism. While no significant difference was observed in body weight and fasting blood glucose levels
among these three groups, L-DKO mice exhibited enhanced glucose tolerance in the condition of HFD feeding for 5 weeks (Fig. 8a–c). Plasma insulin levels of L-Ampka1 KO mice were higher than those in L-Ampka1 WT mice and the levels were drastically decreased in L-DKO mice on HFD (Fig. 8d). These results indicate that inactivation of hepatic Ago2 can improve glucose metabolism even in an Ampka1-deficient condition where insulin resistance occurs (Fig. 8d–f). Consistently, expression levels of a specific repertoire of MD-miRNAs were constantly decreased in the liver of L-DKO mice, while levels of their targets, Hnf1β, Cav1, and Pgc1α, and genes critical for enhancing mitochondrial function were higher in the liver of L-DKO mice compared to L-Ampka1 WT or L-Ampka1 KO mice (Fig. 8g). Taken together, these results suggest that the effect of hepatic Ago2-deficiency on glucose metabolism overrides that of AMPKα1 functions and that a cellular condition which leads to activation of AMPK, but not a direct activation per se, is an important factor that improves glucose metabolism observed in L-Ampka1 KO mice.

Discussion

The role of RNA silencing in suppressing mRNA translation gives rise to the intriguing hypothesis that the RNA silencing machinery might be tightly integrated with the regulation of basal metabolic activity and energy homeostasis, as mRNA translation requires a massive amount of energy. In this study, we uncovered that hepatic Ago2 regulates expression of specific miRNAs that silence genes critical for glucose and lipid metabolism and reduces mRNA translation. These Ago2’s functions appear to intimately be linked to energy metabolism by balancing energy production and consumption through regulating specific mRNA expression and general mRNA translation. Changes in hepatic Ago2-mediated energy balance between energy production and consumption in response to nutrient challenges appears to contribute to the pathogenesis of obesity-associated sequelae (Fig. 8h).

Although Ago1 and Ago2 share functional similarities in RNA silencing, our study provides evidence that Ago2 has a distinct role in metabolic regulation. Hepatic Ago1 is dispensable for obesity-induced pathophysiology, as deletion of hepatic Ago1 did not affect diet-induced weight gain, glucose tolerance, or insulin sensitivity. This, in turn, highlights one of the unique functions of Ago2 in regulating the specific miRNA expression and mRNA silencing. While Ago2-deficiency in the liver affects expression of a small proportion of miRNAs, we demonstrated that Ago2 play a critical role in expression of a subset of specific miRNAs, including miR-802, miR-103/107, and miR-148a/152, which are known to negatively impact glucose and lipid metabolism. In addition, expression of these miRNAs is enhanced in response to the energy stress conditions of lower insulin availability or sensitivity, in an Ago2-dependent manner. Under these stress conditions, hepatocytes are normally programmed to stimulate glucose production, triglyceride synthesis, and the assembly and secretion of very low-density lipoprotein particles. Hepatic Ago2 is likely integrated into this program through the generation of selective miRNAs, and by mediating subsequent RNA silencing. While this mechanism may be beneficial for the maintenance of systemic energy homeostasis during hypoglycemia, hypermotility, starvation, and developmental processes, it could also accelerate the development of metabolic diseases in excess nutrient conditions. When each of the four Ago proteins are ablated constitutively in mice, only the loss of Ago2 causes embryonic
lethality, whereas loss of other three Ago proteins is dispensable for animal development. Importantly, Ago2’s slicer activity is required for embryonic and perinatal development. It is reasonable to consider a model where Ago2’s unique function regulates energy metabolism not only in the liver but also in other organs during development and in adulthood. This may, at least in part, explain the universal importance of Ago2 in such a diverse array of mammalian organs.

In this study, we demonstrated that Ago2-mediated RNA silencing connects the regulation of energy supply with protein biosynthesis. This mechanism may be the core of a vicious cycle in disrupted energy metabolism in the obese liver. In this setting, despite a robust activation of the mTORC1 pathway, protein biosynthesis is progressively suppressed, which is a paradox of mRNA translation.

While obesity is traditionally considered a state of over-nutrition, recent studies suggest that the obese liver may, in some aspects, resemble a condition of energy deprivation in which proper catabolic processes are impaired due to the repression of oxidative phosphorylation pathways and mitochondrial gene expression. Consistently, obesity is also known to induce defects in autophagy in the liver, which leads to poor mitochondrial quality control. As a result, protein biosynthesis may be impaired due to under-powered energy supply even during the activation of the mTORC1 pathway, leading to further accumulation of energy sources. Conversely, hepatic Ago2-deficiency increases expression of key metabolic genes including Ampkα1 with enhanced cellular energy consumption that can lead to lower ATP/ADP ratio. This condition can amplify activation of AMPK and its substrates ULK1, MFF, and Pgc1α, leading to improved mitochondrial capacity and quality, which in turn generates sufficient energy for protein biosynthesis. Of note, Ago2 is also known to regulate mRNA silencing through interacting with exonuclease complexes, the Ccr4-NoT and Pan2-Pan3 complexes, in a miRNA-independent manner, which likely contributes to suppression of protein translation and energy metabolism in the liver. These Ago2-mediated molecular events may solve the paradox of protein biosynthesis in the obese liver, demonstrate a new mechanism in the regulation of basal metabolic activity, and provide a novel therapeutic target for metabolic diseases.

In conclusion, our results highlight that Ago2 uniquely regulates energy production and consumption in the liver, and suggest hepatic Ago2-mediated RNA silencing is a key regulator of glucose and lipid metabolism during the pathogenesis of obesity. We also posit that there may be important translational implications for our findings, especially in the design of therapeutic interventions, to target modulation of a spectrum of Ago2-dependent miRNA-mediated events, in chronic metabolic disorders, such as diabetes, fatty liver diseases, and other obesity-associated sequelae.

**Methods**

**Mice.** Animal care and experimental procedures were performed according to procedures approved by the animal care committees of Cincinnati Children’s Hospital Medical Center. Ago2fl/fl, Ago2cyf/f, and Albumincre/cre were obtained from the Jackson Laboratory (Stock No: 019001, 016520, and 003574, respectively). Ampkα1fl/fl mice were kindly provided by Dr. Basilia Zingarelli. All mice used in this study were on C57BL/6 background. Mice were placed on a high-fat diet (HFD: 60% fat, 20% protein, and 20% carbohydrate kcal; Research Diet #D12492) for 14 weeks old. Liver tissues were excised from mice, and stored in RNAlater (Invitrogen) treatment. Liver tissue was homogenized with Qiazol (Qiagen). Total RNA, including miRNA, was extracted using the miRNeasy Micro Kit (Qiagen). Total RNA, including miRNA, was extracted using the mirNeasy Micro Kit (Qiagen). Quantiitative real-time PCR analysis was performed using SYBR Select Master Mix (Applied Biosystems) in a real-time PCR machine (Qubit) and stored in BioRad qPCR machine. The total RNA was used and real-time PCR were carried out for mature miRNA quantification. Primary miRNAs were quantified using TaqMan Pri-miRNA assays. Sn0202 and β-actin were used as internal controls.

**Biochemical reagents and antibodies.** All biochemical reagents were purchased from Sigma-Aldrich unless otherwise indicated. Antibodies against, JNK1 (SC-180656, 1:5000), and β-tubulin (SC-9104, 1:5000) were from Santa Cruz Biotechnology. Anti-β-actin (SC-47778, 1:2500) and anti-phospho-AMPKα (SC-5035, 1:2500) were from Cell Signaling Technology. Anti-IRS1 (SC-1502) and anti-phospho-IRS (SC-377) antibodies were purchased from Upstate Biotechnology, and anti-Ago2 (SC-1923, 1:2500) was purchased from Abcam.

**Primary hepatocytes.** Hepatocytes were isolated from liver of 12–14 weeks old L-Ago2 WT and L-Ago2 KO mice by a two-step perfusion method with a slight modification. Briefly, the liver was first perfused with 30 ml of HBSS supplemented with 10 mM HEPES, 0.5 mM EGTA and 5 mM glucose and then digested with 35 ml of Collagenase X, Wako at 100 U/ml dissolved in HBSS buffer supplemented with 10 mM HEPES and 5 mM CaCl2. Liver was collected after perfusion and hepatocyte were released and sedimented at 60 × g for 2 min. Hepatocyte suspension was then layered on a 40% percoll solution (GE Healthcare Life Sciences) and centrifuged at 800 × g for 10 min. The alive hepatocytes were recovered from the bottom of the tube and seeded on culture plates.

**Mouse embryonic fibroblasts.** Ago2-deficient fibroblasts reconstituted with Ago2 WT or DA mutant that were kindly provided by Dr. Eric Lai. We also generated Ago2fl/y MEFs through the ST3 protocol and performed an adenosine-mediated gene transfer for Cre or LacZ expression to obtain Ago2fl/y, total HFD HEPS and 5 mM CaCl2. Liver was collected after perfusion and hepatocyte were released and sedimented at 60 × g for 2 min. Hepatocyte suspension was then layered on a 40% percoll solution (GE Healthcare Life Sciences) and centrifuged at 800 × g for 10 min. The alive hepatocytes were recovered from the bottom of the tube and seeded on culture plates.

**Quantitative real-time PCR analysis.** For mRNA quantification, total RNA was extracted using Trizol reagent (Invitrogen). Total RNA was converted to first strand cDNA using SuperScript II ™ cDNA Synthesis Kit (Invitrogen). Quantitative real-time PCR analysis was performed using SYBR Select Master Mix (Applied Biosystems) in a real-time PCR machine (Qubit) and stored in BioRad qPCR machine. The total RNA was used and real-time PCR were carried out for mature miRNA quantification. Primary miRNAs were quantified using TaqMan Pri-miRNA assays. Sn0202 and β-actin were used as internal controls.

**High-throughput sequencing of miRNA.** Liver tissues were excised from mice, and stored in –80 °C after RNA later (Invitrogen) treatment. Liver tissue was then homogenized with Qiazol (Qiagen). Total RNA, including miRNA, was extracted using the mirNeasy Micro Kit (Qiagen). High-throughput sequencing of miRNA was processed according to TrueSeq Small RNA Sample Preparation Guide (Illumina). Briefly, the total RNA was run on an agarose gel and the band corresponding to the size of miRNAs was cut out for further processing. Sequencing adapters were ligated to the size-selected RNA molecules, followed by reverse transcription to obtain the cDNA library, which was subsequently sequenced by Illumina HiSeq2500.
Bioinformatic analysis of miRNA seq. Adapter sequences were removed with fastx_toolkit (v0.10.14, -a TGGAATTCGAGGCTGACGAGG -15 -M 20, http://hannonlab.cshl.edu/fastx_toolkit/) for NCD (Fig. 1a) and S961 (Fig. 3d) samples, and TrimGalore (v0.3.43, -e 0.1 -q 0.1 -O 1 -t AGATCGGAAGACACGCTTC, https://bioinformatics.ubabraham.ac.uk/projects/trim_galore/), and Cutadapt (v1.9.1, http://cutadapt.readthedocs.io) for HDF samples (Fig. 6a), with reads that became shorter than 15 bases, remaining reads were filtered with the FASTX toolkit to quality threshold of at least 90% of the reads. To get raw counts for each mature miRNA, miRExpress (v2.1.2, http://mirexpress.mcb.nctu.edu.tw/) was used to align and create expression count profiles with default parameters. The alignment step (alignSim) used a miRNA precursor file (mmu_mirna.tar) supplied with the miRExpress v2.1.4 and the analysis step used mmu_mirna.tat with mature miRNA information for precursor sequences. Raw counts were normalized using DESeq2 (v1.8.0, http://bioconductor.org/packages/releases/bioc/html/DESeq2.html), to compare mature miRNAs’ relative abundance. Differentially expressed miRNAs were predicted also using DESeq2. For NCD (Fig. 1a) and HDF samples (Fig. 6a), we applied [fold change] > 2 × and adjustment for multiple testing correction (Benjamini-Hochberg) to obtain significantly upregulated miRNAs (threshold of p < 0.005). Heatmaps were created by the pheatmap package (https://cran.r-project.org/web/packages/pheatmap/index.html).

miRNA target enrichment analysis. To predict the enriched target pathways, we used the miPath web-server (v3, http://sif-mirPath.cme.ohioState.edu); we chose KEGG (http://www.genome.jp/kegg/) database as a reference and p < 0.05 and MicrotRNA threshold < 0.8 as filters to get significantly enriched KEGG pathways.

Protein extraction and immunoblot analysis. To prepare protein lysates, cells were washed with cold PBS, followed by lysis in cold mammalian cell lysis buffer [MCLB: 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 10 mM NaF, 5% glycerol, 1% NP-40, 1 mM DTT, and 1× protease and phosphatase inhibitor cocktails]. After homogenization on ice, the cell lysates were centrifuged, and the supernatants were used for western blot analyses. For preparation of liver tissue lysates, the tissues were placed in a cold MCLB and homogenized on ice. The tissue lysates were centrifuged, and the supernatants were used for further experiments. Uncropped scans of immunoblots are shown in Supplementary Fig. 9.

Morphological and immunohistochemical analysis of hepatic and pancreatic tissues. Liver and pancreas were taken, fixed with 10% formalin, and paraffin-embedded sections were prepared for further analysis. Paraffin sections were stained with HE and Periodic Acid-Schiff (PAS) for morphological analyses. For the immunohistochemical staining, the following primary antibodies were used: guinea pig polyclonal anti-insulin (Abcam) and rabbit monoclonal anti-glucagon (Abcam). The following secondary antibodies were used: Alexa Fluor 488–conjugated AffiniPure Goat Anti-Guinea Pig (Jackson Immunoresearch) and Alexa Fluor 594–conjugated AffiniPure Goat Anti-rabbit IgG (Jackson Immunoresearch). The nuclei were stained using 4′,6-diamidino-2-phenylindole (DAPI), and sections were mounted with fluorescence mounting medium (Electron Microscopy Science). Images were acquired on a Nikon 90i Upright. ImageJ was used to process the images.

Palmitate and acetate oxidation assays. Seahorse Bioscience XF249 extracellular Flux Analyzers were used53 to detect palmitate oxidation in primary hepatocytes. Palmitate oxidation was measured by oxygen consumption rate (OCR) with modification. Primary hepatocytes were seeded at a density of 6000 cells per well of a XF249 cell culture microplate and incubated in William E supplemented with 10% FBS. Next day, cells were cultured with DMEM (5.5 mM glucose) supplemented with 10% FBS for 2 h. Cells were washed twice with PBS and were cultured with or without Bt-cAMP or pCPT-cAMP for 2 h. Cells were cultured in medium with 5% DMSO and 2 μM rotenone for 5 h. Mitochondrial DNA copy number was determined using qPCR57. Glucose production assay. Mouse primary hepatocytes were cultured in 12-well plates (0.4 × 106 cells per well) in William E supplemented with 10% FBS. Next day, cells were cultured with 1 ml of DMEM (5.5 mM glucose) supplemented with 10% FBS for 2 h. Cells were washed twice with PBS and were cultured with or without Bt-cAMP or pCPT-cAMP for 3–4 h to serum starvation with FBS-free DMEM (5.5 mM glucose). After washing twice with PBS, cells were cultured in 0.4 ml of glucose production buffer consisting of glucose-free DMEM (pH 7.4) without phenol red supplemented with 20 mM sodium lactate, 2 mM sodium pyruvate, 2 mM l-glutamine and 15 mM HEPES58. Cells were incubated at 37 °C for 1 h with or without Bio-CAMP and Bio-CAMP®. Both medium and cells were collected. The glucose concentration was measured with the Autotik Glucose (WAKO) and was normalized by the total protein content.

Mitochondrial isolation. Liver tissue samples were minced and kept in ice-cold PBS containing proteinase inhibitor immediately after harvest. Tissue were then homogenized in resuspension buffer (RBB/EDTA (10 mM Tris pH 6.7, 10 mM NaCl, 0.1 mM EDTA pH 8.0)) containing proteinase inhibitor. The homogenized samples were filtered through 30-μm filter and sucrose concentration was then adjusted to 250 mM by adding 2 M sucrose. The suspension was centrifuged at 540 G for 3 min at 4 °C and the supernatant was collected for further separation. Crude mitochondrial fraction for functional analysis was sedimented from the supernatant by centrifugation at 9650 × g for 10 min at 4 °C. To prepare pure mitochondria, the crude mitochondria were resuspended in ice-cold separation buffer, mixed with anti-TOM22 MicroBeads and enriched on a MACS column (Miltenyi Biotec). Magnetically purified mitochondria were incubated with 100 μg ml⁻¹ of RNase for 30 min at 4 °C and 10 μl of lysis buffer was added. Mouse liver and pancreas were isolated and pelleted and kept in −80 °C until use.

Luciferase assay. Luciferase plasmids harboring the AmpA1 3′ UTR were generated as follows. AmpA1 3′ UTR were amplified by using primers: 5′-CCCGG ATCTCATTAGTTGCAGCTG-3′ and 5′-GCATCCGAGGTTCCCTTTC ATGAGAAATACAC-3′, and cloned into EcoRI and XhoI restriction enzyme sites of plasmids pRL-SV40 and pRL-CMV, respectively. All plasmids were transferred to CHO-K1 cells by lipofection. Firefly luciferase (pGL4.10) and Renilla luciferase (pRL-CMV) or control (pRL-SV40) reporters were co-transfected into CHO-K1 cells, and luciferase activity was measured using the Dual-Luciferase Reporter assay system (Promega).
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer's instructions. Primer sequences used to mutate the miR-148/miR-152 binding site in the AmpliK are the following: 5'-CTGATACCTTGGCATTTTACGATGCTAAAGATGCTGCTGTACG-3' and 5'-CATTGGCTGCGGGATATCAGGTGATCTTACGATGCTGCTGTACG-3'. The mutated residues are indicated in bold. Mouse primary hepatocytes were plated at a density of 0.8 × 10^5 cells per well of 24-well plate, and transfected with 0.5 μg of each control (pEXZ-MT06), Ampkα (Prkaa1) (MmTo24101-MT06) and Ampkα mutant using Lipofectamine 3000 (Life Technologies) according to the manufacturer's instructions. The transfected cells were incubated with DMEM (5.5 mM glucose) with 10% FBS media for 8 h. Luciferase activities were measured with Luc-Pair Duo-Luciferase Assay Kit 2.0 (GeneCopoeia) and GloMAX 96 Microplate Luminometer (Promega).

Polysome profiling. Preparations of cellular extracts for polysome profiles, sucrose gradient centrifugation, and profile recording 29. Heparin was omitted from lysates used to analyze Ampkα, Cs, and β-actin mRNAs by qRTPCR due to its inhibitory effect on the PCR. Sucrose gradient fractions were collected by upward displacement, and 50 μg of synthetic luciferase mRNA (Promega) and 15 μg of GlycoBlue (Life Technologies) were added to each fraction to control for extraction and PCR efficiency and to improve RNA recovery, respectively. After extraction and precipitation of RNA from sucrose fractions 29, precipitated RNA was washed twice with ice-cold 70% ethanol, dried, and resuspended in RNAase-free H2O. Equal volumes of RNA from each fraction were subjected to cDNA synthesis and qRT-PCR analysis. Levels of Ampkα, Cs, and β-actin mRNAs in each fraction were normalized to luciferase mRNA and plotted as the percentage of total mRNAs from all 12 fractions.

Statistical analysis. Experimental results were shown as the mean ± SEM. The mean values for biochemical data from each group were compared by Student's t-test. Comparisons between multiple time points were analyzed using repeated-measures analysis of variance, two-way ANOVA. Analyses of miRNA sequencing were done by DESeq2.

Data availability. The RNA-Seq data generated in this study have been deposited in the NCBI Sequence Read Archive (SRA, http://www.ncbi.nlm.nih.gov/sra) under the BioProject ID PRJNA395686. The accession codes are SAMN07415658, SAMN07415659, SAMN07415660, SAMN07415661, SAMN07415662, and SAMN07415663 for the NCD study, SAMN07415764, SAMN07415765, SAMN07415768, SAMN07416029, SAMN07415767, SAMN07415769, SAMN07417568, SAMN0741630, SAMN07416306, SAMN07416307, SAMN07416038, and SAMN07416039 for the S961 study, and SAMN07413900, SAMN07413906, SAMN07413907, SAMN07413949, and SAMN07413951 for the HFD study. All other data supporting the findings of this study are available from the corresponding author on reasonable request.

Received: 2 February 2018 Accepted: 26 July 2018
Published online: 10 September 2018

References
1. Smith, B. W. & Adams, L. A. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 7, 456–465 (2011).
2. Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic endoplasmic reticulum translatome by obesity and fasting. Nutr. Rev. 69, 37–49 (2011).
3. Goedeke, L. et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat. Med. 21, 1280–1289 (2015).
4. Soronen, J. et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol. Rep. 4, e12661, 1–14 (2016).
5. Issaro, J. J. & Joshua-Tor, L. From guide to target: molecular insights into eukaryotic RNA interference machinery. Nat. Struct. Mol. Biol. 22, 20–28 (2015).
6. Meister, G. Argonaute proteins: functional insights and emerging roles. Nat. Rev. Genet. 14, 447–459 (2013).
7. Winter, J., Jung, S., Keller, S., Gregory, R. I. & Diederichs, S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11, 228–234 (2009).
8. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).
9. Chelouh, S., Dos Santos, C. O., Chong, M. M. & Hannon, G. J. A dicer-independent microRNA biogenesis pathway that requires Ago catalysis. Nature 465, 584–589 (2010).
10. Yang, J. S. et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc. Natl Acad. Sci. USA 107, 15163–15168 (2010).
11. O’Carroll, D. et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 21, 1999–2004 (2007).
12. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437–1441 (2004).
13. Valdmanis, P. N. et al. Expression determinants of mammalian argonaute proteins in mediating gene silencing. Nucleic Acids Res. 40, 3704–3713 (2012).
14. Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524 (2014).
15. Carrer, M. et al. Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*. Proc. Natl Acad. Sci. USA 109, 15330–15335 (2012).
16. Lu, L. et al. MicroRNA-130a and -130b enhance activation of hepatic stellate cells by suppressing PPARgamma expression: a rat fibrosis model study. Biochem. Biophys. Res. Commun. 465, 387–393 (2015).
17. Huang, J. Y. et al. MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1alpha and PAPARgamma. RNA Biol. 21, 385–400 (2015).
18. Park, J. E. et al. Dicer recognizes the 5′-end of RNA for efficient and accurate processing. Nature 475, 201–205 (2011).
19. Tsuchi, A., Kawamata, T., Izumi, N., Seitz, H. & Tomari, Y. Recognition of the pre-mRNA structure by Drosophila Dicer-1. Nat. Struct. Mol. Biol. 18, 1153–1158 (2011).
20. Liu, Y. P. et al. Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs. RNA Biol. 12, 92–100 (2015).
21. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73 (2014).
22. Gerlach, D., Kriventseva, E. V., Rahman, N., Vejnar, C. E. & Zdobnov, E. M. miRortho: computational survey of microRNA genes. Nucleic Acids Res. 37, D111–D117 (2009).
23. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1091–D1096 (2014).
24. Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699–707 (2018).
25. Del-Aguila, J. L. et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Nat. Genet. 50, 699–707 (2018).
26. Schaffer, L. et al. A novel high-affinity peptide antagonist to the insulin receptor. Biochem. Biophys. Res. Commun. 376, 380–383 (2008).
27. Perry, R. J. et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016).
28. Lu, Y. et al. ELAVL1 modulates transcriptome-wide miRNA binding in normal and macrophages. Cell Rep. 9, 2330–2343 (2014).
29. Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Violette, B. Metformin from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
42. Burkewitz, K., Zhang, Y. & Mair, W. B. AMPK at the nexus of energetics and aging. Cell Metab. 20, 10–25 (2014).
43. Morita, S. et al. One Argonaute family member, Eif2c2 (Ago2), is essential for development and appears not to be involved in DNA methylation. Genomics 89, 687–696 (2007).
44. Wang, D. et al. Quantitative functions of Argonaute proteins in mammalian development. Genes Dev. 26, 693–704 (2012).
45. Lykke-Andersen, K. et al. Maternal Argonaute 2 is essential for early mouse development at the maternal-zygotic transition. Mol. Biol. Cell. 19, 4383–4392 (2008).
46. Su, H., Trombly, M. I., Chen, J. & Wang, X. Essential and overlapping functions for mammalian Argonautes in microRNA silencing. Genes Dev. 23, 304–317 (2009).
47. Fu, S. et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473, 528–531 (2011).
48. Crescenzo, R. et al. A possible link between hepatic mitochondrial dysfunction and diet-induced insulin resistance. Eur. J. Nutr. 55, 1–6 (2016).
49. Singh, R. et al. Autophagy regulates lipid metabolism. Nature 458, 1131–1135 (2009).
50. Yang, L., Li, P., Fu, S., Calay, E. S. & Hotamisligil, G. S. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 11, 467–478 (2010).
51. Madiraju, A. K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014).
52. Jonas, S. & Izaurralde, E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat. Rev. Genet. 16, 421–433 (2015).
53. Giles, D. A. et al. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat. Med. 23, 829–838 (2017).
54. Stemmer, K. et al. Thermoneutral housing is a critical factor for immune function and diet-induced obesity in C57BL/6 nude mice. Int. J. Obes. 39, 791–797 (2015).
55. Arruda, A. P. et al. Chronic enrichment of hepatic endoplasmic reticulum-mitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 20, 1427–1435 (2014).
56. Zhang, C., Seo, J. & Nakamura, T. Cellular approaches in investigating Argonaute2-dependent RNA silencing. Methods Mol. Biol. 1680, 205–215 (2018).
57. Rooney, J. P. et al. PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol. Biol. 1241, 23–38 (2015).
58. Sakai, M. et al. CITED2 links hormonal signaling to PGC-1alpha acetylation in the regulation of gluconeogenesis. Nat. Med. 18, 612–617 (2012).
59. Teng, T., Mercer, C. A., Hexley, P., Thomas, G. & Fumagalli, S. Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol. Cell Biol. 33, 4660–4671 (2013).
60. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).

Acknowledgements

We thank Drs. James Wells, Harinder Singh, David A D’Alessio, and Vivian Hwa for their scientific input and discussion. We also thank Drs. Rebekah Karns, Taishi Kimura, and Kohori Ikeda for their bioinformatics and technical supports and Dr. Eric Lai for generously providing us Ago2-deficient fibroblasts. This work was supported by National Institute of Health (NIH) (R01DK107530). T.N. was supported by the PRESTO from the Japan Science and Technology Agency. A part of this study was supported by grants from NIH (R01DK099222) to S.D. and P30DK078392 for the Digestive Disease Research Core Center in Cincinnati.

Author contributions

T.N. conceived the research. C.Z., T.H., M.T.W., S.D., N.R.Q., C.A.M., H.S. and T.N. designed the methodology and experiments. C.Z., J.S., K.M., E.S.B.S., E.B., V.J.B., K.C., C.L.Y., C.C.C., X.C., N.R.Q., H.E.T. and T.N. conducted experiments. C.Z. and T.N. wrote the manuscript with inputs from all authors.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-05870-6.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.